Drugs / Icenticaftor
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04587622 | Oct 2020 → Sep 2022 | liver failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02190604 | Jul 2012 → Nov 2015 | cystic fibrosis | Novartis Pharmaceuticals | Terminated | Met primary |
| Phase 24 trials · 3 missed | ||||||
| Phase 2 | NCT04396366 | Feb 2021 → Jun 2023 | bronchiectasis | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04268823 | Sep 2020 → Sep 2022 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT04072887 | Sep 2019 → Oct 2021 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT02449018 | Apr 2015 → Dec 2016 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Icenticaftor | “The aim of this phase IIb dose-finding study was to compare a CFTR potentiator, icenticaftor (QBW251), with placebo in patients with COPD and chronic bronchitis.” PMID 37411039 ↗ Aug 2023 |
| Known as | QBW251 | “The aim of this phase IIb dose-finding study was to compare a CFTR potentiator, icenticaftor (QBW251), with placebo in patients with COPD and chronic bronchitis.” PMID 37411039 ↗ Aug 20235“Single oral dose of 300 mg of icenticaftor (QBW251)” NCT04587622 ↗ |
| Action | Activate | “an oral potentiator of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) channel” PMID 33293212 ↗ Dec 2020 |
| Modality | Small molecule | — CHEMBL4650318 ↗ |
| Route | Oral | “Capsule - oral dose” NCT02190604 ↗ |
| Target | CFTR | “an oral potentiator of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) channel” PMID 33293212 ↗ Dec 2020 |